NeOnc appointed Nasim Shomali to its Board as a Class II director, effective July 1, 2026, following the immediate resignation of Ming-Fu (Alan) Chiang.
| IndividualMing-Fu (Alan) Chiang, M.D., Ph.D., MBANasim Shomali | RoleClass II director; member of Scientific Advisory BoardClass II director | Type of ChangeResignedAppointed/Elected | Effective DateJune 27, 2026July 1, 2026 | ReasonNot the result of a disagreement with the Company on any matter relating to the Company's operations, policies, or practicesNot disclosed | Replacement InfoNasim Shomali elected to BoardNot applicable | Background DetailsNot disclosedStrategy Executive at Accenture (Apr 2013–Apr 2026); advised Fortune 20 executives on enterprise strategy; MBA (UCLA Anderson); dual BAs in Bioengineering and Mathematics (Univ. of Washington); Yale Sustainable Leadership program | Board/Committee Role ChangesResigned from Scientific Advisory BoardNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.